Quotes 5-day view Delayed Nasdaq
10/21/2020
10/22/2020
10/23/2020
10/26/2020
10/27/2020
Date
302.57(c)
303.79(c)
299(c)
301.28(c)
300.77 Last
154 372
238 052
239 014
88 344
151 776 Volume
+0.89% +0.40% -1.58% +0.76% -0.17% Change
Sales 2020
339 M - -
Net income 2020
-1 361 M - -
Net cash position 2020
3 129 M - -
P/E ratio 2020
-22,5x
Yield 2020
-
Sales 2021
716 M - -
Net income 2021
-1 065 M - -
Net cash position 2021
1 809 M - -
P/E ratio 2021
-26,0x
Yield 2021
-
Capitalization
27 097 M 27 097 M -
EV / Sales 2020
70,8x
EV / Sales 2021
35,3x
Nbr of Employees
4 200
Free-Float
69,8%
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).
Notations Surperformance© of BeiGene, Ltd.
Trading Rating : Investor Rating :
All news about BEIGENE, LTD.
News in other languages on BEIGENE, LTD.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BEIGENE, LTD.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
16
Average target price
241,89 $
Last Close Price
299,00 $
Spread / Highest target
5,69%
Spread / Average Target
-19,1%
Spread / Lowest Target
-47,2%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
